Article Text

Download PDFPDF

FeNO monitoring to adjust treatment in asthma: has it come of age?
  1. Dominick E Shaw
  1. Correspondence to Professor Dominick E Shaw, Respiratory Research Unit, University of Nottingham, Nottingham NG7 2RD, UK;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Asthma guidelines around the world urge healthcare professionals to use the lowest dose of inhaled corticosteroid (ICS) to achieve asthma control, normally defined as achievement of best lung function, reduction in symptoms and reduction of future exacerbation risk.1 At first glance, this approach seems sensible. Long-term ICS use has appreciable side effects and there is evidence that targeting symptoms with increased ICS doses results in improved outcomes. This approach already forms the backbone of the budesonide/formoterol or beclometasone/formoterol as maintenance and reliever therapy (SMART/FMART), and more recently quadrupling ICS doses during a period of worsening symptoms has been shown to lead to improved outcomes in adults.2

However, life is rarely that simple. One of the main physiological effects of ICS, reduced eosinophilic airway inflammation, is not firmly linked to key asthma parameters namely variable airflow obstruction, airway hyper-responsiveness and symptoms.3 This heterogeneity in asthma mechanisms and a call to redefine how we classify airway disease, is well covered in the recent Lancet Commissions article. In this article, the authors suggest that ICS treatment is not escalated unless biomarkers of type 2 inflammation are increased.4 The two most readily available biomarkers are blood or sputum eosinophil counts and the fraction of nitric oxide in exhaled breath (FeNO).5

With this in mind, Petsky and colleagues6 enter the arena with a systematic review and meta-analysis of tailoring asthma treatment on markers of eosinophilic inflammation. They synthesised the evidence from 3 Cochrane reviews and 22 randomised controlled studies, across a range of patient populations, where asthma treatment was tailored using FeNO or sputum eosinophil counts and outcomes compared with a control population. The main outcome was asthma exacerbations as defined by the individual study authors, but mostly referring to a new course of oral corticosteroids (although some papers included antibiotics too).

Pestky et al found that participants randomised to the FeNO strategy were significantly less likely to have exacerbations when compared with participants managed by a control strategy. The numbers for adults were OR=0.60 (95% CI 0.43 to 0.84) and for children 0.58 (95% CI 0.45 to 0.75). Using sputum eosinophil counts as a guide to ICS therapy the numbers were similar: OR=0.36 (95%CI 0.21 to 0.62). However, there were no significant group differences for either strategy on daily ICS dose at the end of the study, asthma control or lung function. Unfortunately, the potentially more meaningful total ICS exposure over the study (area under the curve) could not be calculated. Based on their data, the authors conclude that ‘at present, despite their popularity, there is insufficient evidence to advocate their use (sputum eosinophils or FeNO) in routine clinical practice’. Some readers may be surprised by this, given the reduction in exacerbations presented, so how does this statement fit with current guidance?

In April 2014, NICE (England’s National Institute for Health and Care Excellence) recommended the use of FeNO as an option to help diagnose asthma in adults and children and to support asthma management in people who were symptomatic despite using ICS. No specific cut points were given for FeNO-based management (diagnosis or dose titration). The review identified four studies; cut-offs for the highest sum of sensitivity and specificity for diagnosis ranged from 20 ppb to 47 ppb for FeNO. Sensitivities ranged from 32% to 88%, and specificities from 75% to 93%. Consequently the External Assessment Group at NICE concluded that it was difficult to identify the optimal cut-off for sensitivity and specificity of FeNO; however, its general use was recommended.

In November 2017, NICE published further guidance on the diagnosis, monitoring and chronic asthma management. This recommended using a FeNO of 40 ppb or more in adults, and 35 ppb or more in children or young people, to help diagnose asthma. It stated against using FeNO to monitor asthma control but referred back to the previous 2014 guideline for supporting asthma management in people who were still symptomatic despite appropriate ICS use.

Given the recommendations from NICE, where does this leave FeNO as a tool for titrating ICS dose in asthma? A reduction in exacerbations is an important outcome, and as this latest meta-analysis shows, this can be achieved using FeNO measurements to guide therapy. Reducing exposure to a potentially toxic treatment (oral corticosteroids) is important for our patients and it is one of the main criteria used by payers to assess cost effectiveness of asthma interventions. The finding of a lack of efficacy on lung function or asthma control does fit with the paradigm that symptoms and inflammation are not always in step and should therefore not predicate against the use of FeNO. The lack of reduction in overall ICS dose is also not a major concern; presumably the increased dose of ICS in those with high FeNO is counterbalanced by a reduction in those with a low FeNO. Furthermore, FeNO meets many requirements for routine clinical use (standardised, easy to preform, relatively cheap, repeatable).

The key issue is therefore cut points for FeNO. Hard cut points for titrating treatment (up or down) have not yet been reliably identified. There are several reasons for this. FeNO has traditionally been used as marker of eosinophilic inflammation, but it does not have a direct causal relationship and may better reflect interleukin 13 activity as seen in the studies of Lebrikuzimab.7 8 This is also clearly seen in the studies of Mepolizumab where both blood and sputum eosinophil counts were reduced by therapy, but FeNO did not alter.9 Second as can be seen from the fact that NICE recommend different cut points based on age, one FeNO cut point does not fit all. Normal ranges have been established and they vary based on age, gender, atopy and smoking.10 11 Lastly, the study design and consequent external validity of FeNO studies depends greatly on the control algorithm used. If the control algorithm is set too rigidly, or varies from routine care (ie, attempting to achieve perfect lung function, no symptoms and no rescue short acting beta agonist use at all visits), the control arm is at risk of overtreatment. Although the aim for perfect control is admirable, often some compromise has to be accepted in the real world. Standardising control arms (or using an agreed standard of care) in interventional asthma studies would help study comparison and future meta-analysis. Indeed there is already some evidence for overtreatment; one study found a 348 mcg reduction (25% of total daily dose) was achievable with no difference in annual dose of oral corticosteroids,12 although patients with well-controlled asthma who stop regular low-dose ICS have an increased risk of an asthma exacerbation compared with those who continue.13

There are other considerations when titrating treatment in people with asthma. The evidence that there is a clear dose response relationship between clinical response and treatment dose is mixed; indeed this relationship may plateau above the equivalent of 1000 mcg BDP.14 Furthermore, the dose response relationship between FeNO reduction and increasing ICS dose is flat between 100 mcg and 800 mcg, with no significant changes in FeNO between these doses.15 FeNO levels may be elevated for other reasons, especially nasal polyposis,16 therefore treating the biomarker, and not the patient, may be unwise. Stepping down treatment based on stable FeNO levels to identify those at risk of deterioration has also been attempted; Wilson et al assessed whether a low baseline FeNO predicted successful ICS dose reduction or whether an increase in FeNO following dose reduction predicted deterioration. Neither approach was helpful.17

Although there are interesting data emerging on the use of FeNO to assess compliance to ICS therapy,18 and to predict response to therapy, irrespective of a label of asthma,19 the key question of how best to use FeNO measurements to uptitrate or downtitrate ICS dosing remains. Given the heterogeneity of asthma, allied to the individual versus group mean response to treatment,20 what is required is personalised cut points based on an individual’s FeNO response to initial ICS therapy, with identification of specific cut points for that individual, followed by regular monitoring and treatment escalation based on FeNO variation. Until then, although we know FeNO tells us something important about an individual’s response to ICS, we will be unable to fully understand exactly what.



  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles